American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
Top Cited Papers
Open Access
- 30 May 2008
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (6), 762-784
- https://doi.org/10.1002/art.23721
Abstract
No abstract availableKeywords
This publication has 202 references indexed in Scilit:
- The Successful Use of Adalimumab to Treat Active Crohn's Disease of an Ileoanal Pouch During PregnancyDigestive Diseases and Sciences, 2006
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisThe New England Journal of Medicine, 2006
- Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and MalignanciesJAMA, 2006
- Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre studyAnnals Of The Rheumatic Diseases, 2006
- Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparisonAnnals Of The Rheumatic Diseases, 2006
- Tuberculoses lors de traitements par l’infliximab: Suivi national du 1er janvier 2000 au 30 juin 2003La Presse Médicale, 2005
- Outcome of Pregnancy in Women Receiving Infliximab for the Treatment of Crohn's Disease and Rheumatoid ArthritisThe American Journal of Gastroenterology, 2004
- Leflunomide for the Treatment of Rheumatoid Arthritis in Clinical PracticeDrug Safety, 2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- Long term progression of joint damage in rheumatoid arthritis.Annals Of The Rheumatic Diseases, 1986